GS 9256

Drug Profile

GS 9256

Alternative Names: GS-9256

Latest Information Update: 26 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Hepatitis C

Most Recent Events

  • 05 Sep 2011 Gilead terminates dosing of tegobuvir in patients receiving a four-drug regimen in a phase IIb trial of GS 9256
  • 01 Sep 2011 Pharmacodynamics data from early research in Hepatitis C presented at the 242nd American Chemical Society National Meeting (ACS-2011)
  • 18 Aug 2011 Gilead Sciences completes enrolment in its phase II trial for Hepatitis C in USA, Canada & European Union (NCT01225380)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top